GT Urological has raised $4.56 million from the sale of equity, according to documents filed with the Securities and Exchange Commission.

Thank God for St. Jude Medical, pro-investment legislators and hearing device companies plugged by Rush Limbaugh. Thumbs down to Boston Scientific, a diminishing amount of venture capital and boondoggle business parks.

The University of Minnesota said Wednesday that scientists have established a firm relationship between a protein known as tau and Alzheimer’s disease, the most common form of elderly dementia in the United States.In a study published in the journal Neuron, researchers say that an early buildup of tau in the dendritic spines, a region of [...]

BridgePoint Medical Inc. has raised $9.1 million from the sale of equity. The company based in Plymouth, Minnesota, is developing balloon catheter system to treat chronic coronary and peripheral total occlusions, a condition in which clots frequently clog blood vessels.

The FDA approval of the Endurant system adds yet another stent to the list of Medtronic’s cadriovascular products. The company is relying on new innovative medical devices to continue to grow revenue. Medtronic estimates 1.2 million Americans suffer from abdominal aortic aneurysms, which will be treated by Endurant.

It’s been that kind of day at Medtronic Inc. (NYSE:MDT). In the morning, the company in Fridley, Minnesota, announced current CEO Bill Hawkins would retire next year. In the afternoon, Medtronic announced one of its former CEOs, Winston Wallin, had died at the age of 84.

When Medtronic Inc. (NYSE:MDT) CEO Art Collins retired in 2007, there were at least two top candidates vying to replace him. One was Michael DeMane, the brash president of Medtronic’s spine business whose aggressive pursuit of growth invited legal and regulatory scrutiny. The other was chief operating officer Bill Hawkins, a steady, stabilizing presence within Medtronic’s senior leadership team.

Medtronic Inc. (NYSE:MDT) said Monday that Chairman/CEO Bill Hawkins will retire next year. The medical device giant based in Fridley, Minnesota, said Hawkins, 56, will leave the company April 2011. Medtronic will launch an external search for his replacement.

During its investors presentation, BSX told analysts it could boost earnings per share growth (EPS) by 11-12 percent annually through 2015, mostly through aggressive cost cutting.The company based in Natick, Massachusetts, with major operations in Minnesota also said it would use $7 billion in projected free cash flow to pay down debt, pursue acquisitions, and reserve funds against legal and tax liabilities.Wall Street, though, wondered how BSX could afford to do all of that, especially with sluggish sales growth.

Medtronic Inc. (NYSE:MDT) said Friday that the Food and Drug Administration (FDA) has approved a catheter-based therapy that uses cold temperatures to combat atrial fibrillation (AF). Medtronic inherited Arctic Front in 2008 when it paid $380 million to purchase CryoCath Technologies Inc.